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Tumor angiogenesis is one of the hallmarks of tumor progression and is essential for
invasiveness and metastasis. Myeloid inflammatory cells, such as immature myeloid
precursor cells, also termed myeloid-derived suppressor cells (MDSCs), neutrophils,
and monocytes/macrophages, are recruited to the tumor microenvironment by factors
released by the malignant cells that are subsequently “educated” in situ to acquire
a pro-invasive, pro-angiogenic, and immunosuppressive phenotype. The proximity of
myeloid cells to endothelial cells (ECs) lining blood vessels suggests that they play
an important role in the angiogenic response, possibly by secreting a network of
cytokines/chemokines and inflammatory mediators, as well as via activation of ECs for
proliferation and secretion of pro-angiogenic factors. Interleukin-1 (IL-1) is an “alarm,”
upstream, pro-inflammatory cytokine that is generated primarily by myeloid cells. IL-1
initiates and propagates inflammation, mainly by inducing a local cytokine network and
enhancing inflammatory cell infiltration to affected sites and by augmenting adhesion
molecule expression on ECs and leukocytes. Pro-inflammatory mediators were recently
shown to play an important role in tumor-mediated angiogenesis and blocking their
function may suppress tumor progression. In this review, we summarize the interactions
between IL-1 and other pro-angiogenic factors during normal and pathological conditions.
In addition, the feasibility of IL-1 neutralization approaches for anti-cancer therapy is
discussed.
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INTRODUCTION
Postnatal angiogenesis, first described by Folkman in the 70’s,
referred to a process by which mature endothelial cells (ECs)
proliferate and sprout to create new blood vessels. Usually, quies-
cent ECs are inactive for months and even years; they proliferate
only upon angiogenic activation due to various pathological
conditions (Carmeliet and Jain, 2000; Carmeliet, 2003, 2005;
Ribatti, 2009). Initially, the angiogenic process was considered to
represent the outcome of straightforward interactions between
pro-angiogenic factors and specific signaling receptors on the
membranes of ECs (Folkman, 1995, 2001, 2003; Folkman and
D’Amore, 1996). Althoughmanymolecules are involved in angio-
genesis, VEGF stands out because it has a direct mitogenic effect
on ECs and functions as a key regulator of both physiologi-
cal and pathological angiogenesis (Thomas, 1996; Alitalo and
Carmeliet, 2002; Shibuya, 2006a,b). VEGFA belongs to the VEGF
family and through activation of two tyrosine kinase recep-
tors, VEGFR1 (Flt-1) and VEGFR2 (FLK-1), plays a major role
in the angiogenic response. The biological effects of VEGF are
thought to be mediated mainly by VEGFR2, whereas VEGFR1
can transduce a weak, intracellular signal in ECs and was ini-
tially thought to be a decoy receptor, thus serving as a negative
regulator of angiogenesis (Hiratsuka et al., 1998). At the same
Abbreviations: IL-1, Interleukin-1; IL-1Ra, Interleukin-1 receptor antagonist;
VEGF, Vascular endothelial growth factor; VEGFR, Vascular endothelial growth
factor receptor; TNF, Tumor necrosis factor; TGFβ, Tumor growth factor beta;
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time, VEGFR1 is expressed on different myeloid cells, such as
macrophages and is directly involved in the migration of these
cells to inflammatory areas (Shibuya, 2006a,b). Recently, it was
found that inflammation usually accompanies tumor develop-
ment and the mechanism by which inflammation contributes to
tumor-mediated angiogenesis has been the subject of intensive
study.
Pro-inflammatory cytokines are potent factors in the induc-
tion and support of angiogenesis. Of special relevance to
angiogenesis are the “alarm cytokines” IL-1 and TNFα that are
generated by macrophages immediately after confrontation with
inflammatory stimuli. These stimuli induce the expression of pro-
inflammatory genes in diverse stromal/inflammatory cells, which
ultimately results in a local cascade of cytokines and small effec-
tor molecules that initiate, propagate, and sustain inflammation
(Dinarello, 1996; Apte and Voronov, 2002, 2008; Balkwill, 2002;
Apte et al., 2006a,b; Balkwill and Mantovani, 2012). IL-1 and
TNFα also increase the expression of adhesion molecules on both
ECs and leukocytes, promoting leukocyte infiltration from the
blood into inflamed tissues (Apte and Voronov, 2002, 2008; Apte
et al., 2006a,b).
The direct relationship between inflammation and tumor-
mediated angiogenesis has prompted the development of novel
anti-tumor therapies based on the attenuation of inflammation.
In this review, the interaction of IL-1 molecules with a critical
pro-angiogenic factor, VEGF, and the effects of IL-1 on ECs and
myeloid cells during the angiogenic response are discussed.
www.frontiersin.org March 2014 | Volume 5 | Article 114 | 1
Jincai Luo, Peking University, China
Luca Vannucci, Academy of
Sciences of the Czech Republic,
Czech Republic
*Correspondence:
Elena Voronov, The Shraga Segal
Department of Microbiology,
Immunology and Genetics, Faculty
of Health Sciences and The Cancer
Research Center, Ben-Gurion
University of the Negev, Ben Gurion
Str., PO Box 653, Beer-Sheva 84105,
Israel
e-mail: elena@bgu.ac.il
†Present address:
Yaron Carmi, Department of
Pathology, School of Medicine,
Stanford University, Palo Alto, USA
Voronov et al. The role of IL-1 in tumor-mediated angiogenesis
THE IL-1 MOLECULES
The IL-1 family consists of agonistic and antagonistic molecules,
as well as receptors. The two major agonistic proteins are IL-1α
and IL-1β. The third important molecule is the IL-1 receptor
antagonist (IL-1Ra), which is a physiological inhibitor of pre-
formed IL-1; it binds to IL-1 receptors without transmitting an
activation signal (reviewed in Dinarello, 1996; Stylianou and
Saklatvala, 1998; Sims et al., 2001; Apte and Voronov, 2002,
2008; Arend, 2002; Dinarello, 2002; O’Neill, 2002; Braddock
and Quinn, 2004; Apte et al., 2006a,b; Mantovani et al., 2008;
Mantovani and Sica, 2010).
Many cell types produce and secrete IL-1α, IL-1β, and IL-1Ra
upon activation with microbes, microbial products, cytokines,
and other environmental stimuli, as well as products of dam-
aged tissue (reviewed in Dinarello, 1996, 2006; Apte and Voronov,
2008; Voronov et al., 2013). IL-1α and IL-1β are synthesized
as precursors of 31 kD that are further processed by proteases
to their mature secreted 17 kD forms. IL-1 differs from most
other cytokines by the lack of a signal sequence, thus not passing
through the endoplasmic reticulum-Golgi pathway. The mech-
anisms of IL-1 secretion are not yet completely understood.
IL-1Ra, which has a signal peptide, is secreted in the ER-Golgi
exocytic pathway.
IL-1β is not present in homeostatic conditions; it is induced
and secreted only upon inflammatory signals. The IL-1β pre-
cursor is biologically inactive until it is enzymatically cleaved
into the mature secreted form by the IL-1β-converting enzyme
(caspase-1) that is activated in the cytosol on the inflammasome
platform (reviewed in Dinarello, 2009, 2011a; Eisenbarth and
Flavell, 2009; Franchi et al., 2009; Martinon et al., 2009; Latz,
2010; Schroder and Tschopp, 2010). IL-1β, due to the fact that
it is extensively secreted, has been considered to be the major
pro-inflammatory molecule. At low local doses, IL-1β induces
limited inflammatory responses, followed by activation of spe-
cific immune mechanisms, while at high doses, IL-1β induces
broad inflammation accompanied by tissue damage and immune
suppression (reviewed in Voronov et al., 2013).
IL-1α, in contrast, is present in homeostatic conditions in
many cells. IL-1α is only rarely secreted by living cells and in
most cases is undetectable in body fluids. Its protein is trans-
lated as a precursor (ProIL-1α), which is further processed by
the Ca2+-dependent protease, calpain, into the mature 17 kD
form and the 16 kD N-terminal cleavage product- the propiece
of IL-1α, also known as the IL-1αN-terminal peptide (IL-1NTP).
Intracellular ProIL-1α is present in many cells because they con-
tain calpain inhibitors and are thus unable to process and secrete
IL-1α (Afonina et al., 2011; Di Paolo and Shayakhmetov, 2013;
Zheng et al., 2013). Recently, a novel mechanism to control IL-1α
activity has been described by Zheng et al. (2013) and reviewed in
Di Paolo and Shayakhmetov (2013). Thus, under normal condi-
tions, IL-1α is synthesized as a p33 precursor that is sequestered
in the cytosol by IL-1 receptor type 2 (IL-1R2), where it cannot
be cleaved by proteases or activate IL-1 receptor type 1 (IL-1R1)
signaling. However, under inflammatory signals, after inflamma-
some activation, IL-1R2 is cleaved by caspase-1 and ProIL-1α is
further processed by calpain to the highly active p17mature IL-1α
form, which can be secreted from cells.
A biologically active membrane-associated form of IL-1α
(23 kD) that is anchored to the membrane via a mannose-like
receptor has been observed in activated cells that express the
cytokine. However, it is not clear how IL-1α is inserted into the
membrane.
IL-1α and IL-1β signal through the same IL-1Rs, which belong
to the immunoglobulin (Ig) supergene family and are exten-
sively expressed on many cell types. IL-1R1 (80 kD) is a signaling
receptor, whereas IL-1R2 (68 kD) serves as a decoy target, act-
ing to reduce excessive amounts of IL-1 (reviewed in Apte and
Voronov, 2008; O’Neill, 2008; Dinarello, 2009, 2011b; Garlanda
et al., 2009; Gabay et al., 2010; Sims and Smith, 2010; Voronov
et al., 2013). Following the binding of IL-1 to IL-1R1, a second
chain, i.e., the IL-1R acceptor protein (IL-1RAcP), is recruited.
This heterodimeric complex triggers IL-1 signaling by activating
the IL-1 receptor-associated kinase (IRAK) and ultimately leads to
the activation of NF-κB and its target genes. On the contrary, IL-
1R2 and the IL-1Ra do not form this heterodimeric complex with
the IL-1RAcP and therefore do not recruit IRAK. While IL-1α
and IL-1β signals through the same receptors, they differ dramati-
cally in some biological functions (reviewed in Apte and Voronov,
2008; O’Neill, 2008; Dinarello, 2009, 2011b; Garlanda et al., 2009;
Gabay et al., 2010; Sims and Smith, 2010; Voronov et al., 2013).
The differential effects of these molecules on angiogenesis are
discussed in this review.
THE EFFECTS OF IL-1 ON ECs AND ITS CROSSTALK WITH
PRO-ANGIOGENIC MOLECULES
ECs are the main cells that are involved in both the normal and
pathological angiogenic response. Multiple studies have shown
in vitro effects of recombinant IL-1 on parameters related to
the physiology of ECs, including their activation, as evidenced
by morphological changes, increased migration and proliferation
and ultimately organization into tube-like structures (reviewed
in Voronov et al., 2007, 2010a, 2013; Apte and Voronov, 2008).
As IL-1 is a strong activator of ECs, it induces profound changes
in gene expression and function that allow these cells to partic-
ipate actively in inflammatory reactions, immunity, and blood
vessel formation. For example, IL-1β induces morphological
transformation in human dermal micro-vascular endothelial cells
(HDMECs), accompanied by an increased growth rate, loss of
contact inhibition, and an increase in the permeability of con-
fluent EC monolayers (Bokhari et al., 2006). Nevertheless, it is
not known whether the described effects of IL-1 on ECs are
direct, due to its action, or indirect, due to IL-1-induced cytokines
produced by ECs. It was found that in vitro, IL-1β increases
expression of FGF2 in ECs through activation of NF-κB (Lee and
Kay, 2012) and also induces expression of different chemokines,
cytokines, direct angiogenic factors, and adhesion molecules on
ECs (Breviario et al., 1990; Sica et al., 1990; Kang et al., 2006). In
addition, IL-1β interaction with IL-1R1 on ECs inducesmigration
of the cells and tube formation, mainly via activation of p38-
mitogen-activated protein kinase (MAPK) and MAPK-activated
protein kinase 2 (Jagielska et al., 2012). Moreover, IL-1β up-
regulates expression of VEGF and its receptors on ECs (Berse
et al., 1999) or aortic smooth muscle cells (Stavri et al., 1995;
Maruyama et al., 1999; Nasu et al., 2006) and VEGF secretion
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from these cells was significantly inhibited by the addition of IL-
1Ra. In vivo, IL-1 also plays a synergistic, pro-angiogenic role
with some pro-angiogenic factors (Friesel and Maciag, 1999).
For example, the synergistic effects of VEGF and IL-1 in the up-
regulation of genes of growth factors and inflammatory cytokines
in ECs have been described and a 60% overlapping of genes
induced by each of these cytokines was observed (Schweighofer
et al., 2009). VEGF/IL-1 induced genes comprise mainly a group
of genes with NFAT, as well as NF-κB binding sites in their pro-
moters; VEGF-A preferentially uses NFAT and IL-1 uses NF-κB to
induce these genes. It was also observed that both VEGF and IL-
1β increase the permeability of ECs via a Src-dependent pathway
(Sheikpranbabu et al., 2009).
Using a Matrigel model, we found that both rIL-1β and
rVEGF induce each other and are both essential to induce
an angiogenic response. Thus, neutralization of either of these
cytokines abrogated the angiogenic response. The importance
of the interaction between IL-1β and VEGF was also demon-
strated by the weak angiogenic response observed in Matrigel
plugs loaded with rVEGF inmice deficient in IL-1β or its signaling
receptor (Carmi et al., 2013). Inhibition of VEGFR1 signal-
ing in Matrigel plugs supplemented with recombinant cytokines
(IL-1β or VEGF) abrogated angiogenesis, probably by inhibit-
ing recruitment of bone marrow-derived (BMD) myeloid cells.
Thus, in multiple studies, synergy of IL-1β and VEGF has
been described; however, our studies demonstrate the neces-
sity of both factors in angiogenic responses. IL-1β is also
an essential factor for endothelial precursor cells (EPCs) to
mature into ECs and this IL-1β-induced effect was facilitated
by the addition of VEGF. For example, when either EPCs or
myeloid circulating angiogenic cells from lupus patients were
co-cultured with IL-1β and VEGF, their capacity to proliferate
and differentiate into mature ECs was synergistically increased
(Thacker et al., 2010).
There are fewer studies on the role of IL-1α in angiogenesis.
We found that IL-1α has less potent pro-angiogenic effects com-
pared to IL-1β in its recombinant form (unpublished results).
Nevertheless, in vivo studies on the effects of IL-1α and IL-
1β on angiogenesis revealed that both agonistic molecules are
important, but probably work through different pathways. Thus,
IL-1α can stimulate a high angiogenic response by recruiting
macrophages that are an abundant source of FGF (reviewed
in Sano et al., 1990; Brogi et al., 1993; Dinarello, 1996; Rider
et al., 2011, 2012), or other VEGF-expressing inflammatory cells
(Salven et al., 2002). In addition, a dose-dependent effect of IL-1α
in de novo synthesis of VEGF by human peripheral mononuclear
cells (PBMCs) was shown. This effect was blocked by treatment
with VEGFR2 antibodies, whereas neutralization of VEGFR1
induced only marginal effects. Both in vitro and in vivo, IL-1α
can stimulate ECs to secrete IL-8 and during in vivo angio-
genesis, the source of IL-1 can be from PBMCs or activated
platelets (Kaplanski et al., 1994a,b). IL-1α is also released from
ECs following stress signals, such as starvation or TNF activa-
tion (Berda-Haddad et al., 2011) and in addition, IL-1α activates
ECs to express CXCL1, VCAM-1, and ICAM-1, thus promot-
ing trans-endothelial-migration of inflammatory cells (Thornton
et al., 2010).
IL-1 IN INFLAMMATION-INDUCED ANGIOGENESIS
In the last decade, the link between inflammation and angiogen-
esis has become recognized. Extensive angiogenesis was observed
in chronic inflammation, for example in rheumatoid arthritis and
inflammatory bowel disease (Folkman, 2001, 2003). In both acute
and chronic inflammation, functional changes in the vascula-
ture were found. In acute inflammation, these changes include
an increase in permeability, extensive EC mitotic activity, and
remodeling of capillaries. Upon chronic inflammation, vascular
dilation and an increase in capillary density was observed. During
inflammation, ECs actively recruit immune cells from the circu-
lation into the underlying tissue, where they play a role in angio-
genesis. An increase in growth factor and cytokine production,
due to inflammation, also leads to proliferation of ECs.
The role of the IL-1 molecules in promoting inflammation-
induced angiogenesis was studied by us, using the model of
Matrigel plugs supplemented with supernatants of hypoxic
macrophages, as such, or after activation with LPS as an inflam-
matory stimulus (Carmi et al., 2009). We showed that neutraliza-
tion of IL-1 in supernatants of hypoxic macrophages, particularly
IL-1β, completely abrogated cell infiltration and angiogenesis in
Matrigel plugs, concomitant to dramatically reduced VEGF lev-
els. Supernatants from macrophages of IL-1β knockout (KO)
mice did not induce this inflammatory or angiogenic response.
The importance of IL-1 signaling in the host was demonstrated
by the dramatic reduction of inflammation-induced angiogenic
responses in Matrigel plugs that contained supernatants derived
from WT macrophages implanted in IL-1RI KO mice. Using the
aortic sprouting assay, it was shown that IL-1 does not directly
activate EC migration, proliferation, and organization into blood
vessel-like structures, but rather activates infiltratingmyeloid cells
to produce a cascade of cytokines/chemokines, which further acti-
vate tissue resident ECs to produce direct pro-angiogenic factors,
such as VEGF (Carmi et al., 2009). Similarly, Nakao et al., demon-
strated that ectopic expression of IL-1β in the cornea induces
increased angiogenesis, which is dependent on infiltration of
COX-2-positive macrophages that activate the angiogenic process
in a complex manner (Nakao et al., 2005). An example of an indi-
rect effect of IL-1β on angiogenesis is the pro-angiogenic activity
of osteopontin-treated monocytes on chick embryo chorioallan-
toic membranes that is completely abrogated by neutralization
with anti-IL-1β antibodies (Naldini et al., 2006). In addition, sys-
temic treatment with IL-1Ra prevented the formation of new
blood vessels in corneas impregnated with VEGF or basic FGF
(Coxon et al., 2002). In conclusion, IL-1, most probably the
actively secreted form of IL-1β, functions directly or indirectly
on myeloid infiltrating cells, as well as ECs, and thus regulates
inflammation-induced angiogenic responses.
IL-1 MOLECULES PLAY A KEY ROLE IN THE TUMOR
MICROENVIRONMENT
The induction of angiogenesis is considered to be a hallmark
of cancer and is important for tumor growth and dissemi-
nation (Folkman, 1995, 2001, 2003; Folkman and D’Amore,
1996). An initially developing tumor is dormant until it under-
goes the angiogenic switch, as initially described by Folkman.
During this switch, the balance between the pro-angiogenic and
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anti-angiogenic factors changes and angiogenic stimuli are pre-
dominant. One of the major mechanisms of the angiogenic
switch is enhanced expression and secretion of angiogenic factors,
mainly VEGF, by themalignant cells. However, themechanisms of
the angiogenic switch are not completely elucidated, as detectable
tumors usually have undergone this switch and already have an
established vascular network. As indicated, tumor vascularization
occurs through “classical” angiogenesis, as well as via vasculo-
genesis, which involves cells recruited from the BM (Carmeliet,
2005; De Palma et al., 2005; Bertolini et al., 2006). Thus, cir-
culating VEGFR2-positive cells were shown to be initiators of
vasculogenesis; however, conflicting findings on their ability to
incorporate into newly formed blood vessels at tumor sites have
been reported (De Palma et al., 2003; Gothert et al., 2004; Peters
et al., 2005; Purhonen et al., 2008; Carmi et al., 2013). EPCs were
initially described by Asahara, who reported on their ability to
repair angiogenesis in ischemic tissues (Asahara et al., 1999). It
was found that IL-1β can mobilize EPCs in a VEGF-dependent
manner by regulation of VEGF and VEGFR2 expression on ECs,
thus supporting neovascularization (Amano et al., 2004).
In further studies, a population of hematopoietic cells express-
ing endothelial markers, such as CD31, VEGFR2, and Tie2, was
described and termed myeloid angiogenic cells (MACs) (Medina
et al., 2010). These cells express high levels of pro-angiogenic and
macrophage type 2 markers (Medina et al., 2011) and their func-
tion at the tumor site is still disputed. In some models, MACs
were shown to differentiate into mature ECs that incorporate into
the vasculature (Kawamoto et al., 2001; Urbich et al., 2003); how-
ever, upon intravitreal injection, MACs enhanced vascular repair
of ischemic retinopathy, but preserved their original phenotype
and did not differentiate into mature ECs. In addition, BMD cells
of myeloid origin were shown to be essential for tumor-mediated
angiogenesis. The proximity of BMD cells, including MACs, to
ECs lining blood vessels suggests their paracrine role, facilitating
the EC response during angiogenesis. These cells probably do not
incorporate into blood vessels but function as supporting cells
(Ziegelhoeffer et al., 2004).
Various populations of BMD myeloid cells are found in the
tumor microenvironment. These include circulating monocytes,
Tie-2 expressing monocytes (TEMs), myeloid-derived suppres-
sor cells (MDSCs), tumor-associated macrophages (TAMs) and
neutrophils (reviewed in Murdoch et al., 2008; Wels et al., 2008;
Coffelt et al., 2010; Ferrara, 2010a; Ruffell et al., 2012; Sica et al.,
2012; Chambers et al., 2013; De Palma and Lewis, 2013; Favre
et al., 2013). The precise relationship among the myeloid cell
types is uncertain and it is not known whether they act in the
tumor microenvironment in redundant or specific manners. In
various tumor experimental systems, diverse myeloid cell popula-
tions dominate. Mantovani et al. suggested a unifying hypothesis
that myeloid cells at tumor sites actually represent a continuum
of cell populations that all share properties of M2-macrophages,
which promote tumor-mediated angiogenesis and progression
(Mantovani and Sica, 2010; Allavena and Mantovani, 2012).
Myeloid cells perform paracrine functions in the tumor-mediated
environment, secreting angiogenic factors, and providing the
inflammatory milieu for the angiogenic response. For example,
MDSCs and TAMs secrete VEGF and MMP9, which increases the
bioavailability of VEGF sequestered in the extracellular matrix
by its proteolytic activity (reviewed in Murdoch et al., 2008;
Mantovani et al., 2009; Gabrilovich et al., 2012).
IL-1, as a major hematopoietic and pro-inflammatory
cytokine has dramatic effects on the generation of myeloid cells in
the BM and on their recruitment to tumor sites, as well as on the
in situ phenotype/function of these cells in the tumor microen-
vironment (reviewed in Apte and Voronov, 2008; Voronov et al.,
2013). For example, in vitro, addition of IL-1 to BMCs increases
secretion of VEGF and the total number of BMCs expressing
CD34 or Flk-1 (Qin et al., 2006). Indeed, the absence of IL-
1β in the tumor microenvironment limited the recruitment of
FGF1-producing mononuclear cells to tumor sites (Prudovsky
et al., 2003). Thus, it was suggested that IL-1 can affect BMD
differentiation or induce them to secrete pro-inflammatory or
angiogenic factors (reviewed in Apte and Voronov, 2008; Voronov
et al., 2013), which are also involved in the recruitment of addi-
tional myeloid cells to tumor sites. Indeed, the importance of
the VEGFR1/VEGF-A axis in recruiting myeloid cells that express
VEGFR1 to tumor sites has been noted, and in mice deficient
in VEGFR1, decreased recruitment of macrophages and other
myeloid cells into tumors was observed (Duyndam et al., 2002).
In addition, depletion of VEGFR1 in the renal cell carcinoma
model leads to inhibition of macrophage recruitment to tumors
(Li et al., 2011).
In our studies, the role of microenvironment-derived IL-1
on the recruitment of VEGFR1-positive BMD cells to tumor
sites was confirmed. We characterized a new auto-induction cir-
cuit, IL-1β/VEGF, which acts via interactions between BMDs,
mainly VEGFR1+/IL-1R1+immature myeloid cells (MDSCs) and
to a lesser extent macrophages, and tissue-resident ECs (Carmi
et al., 2013). Myeloid cells do not directly stimulate ECs for
migration, proliferation, and subsequent blood vessel forma-
tion. However, they produce IL-1β and a network of other pro-
inflammatory cytokines/molecules, such as Bv8, CCL2 and CCL3,
etc., which subsequently activate resting tissue-resident ECs to
produce VEGF, as well as other direct pro-angiogenic factors,
such as PlGF and bFGF. Thus, IL-1β provides the inflammatory
microenvironment for angiogenesis and tumor progression. We
have shown that IL-1β inhibition stably reduces tumor growth, by
limiting inflammation and inducing the maturation of MDSCs
into M1 macrophages, which do not promote tumor invasive-
ness and can be cytotoxic/cytostatic for tumor cells. In addition,
M1 macrophages also serve as antigen-presenting cells for induc-
ing anti-tumor immunity. These results suggest that IL-1β, apart
from its ability to affect recruitment of myeloid cells, controls
their maturation or activation for a pro-tumorigenic phenotype
(Song et al., 2005; Bunt et al., 2006; Tu et al., 2008; Carmi et al.,
2013). For example, Hagenmann et al. showed that IL-1R sig-
naling in macrophages is essential for M2 polarization induced
by conditioned medium of tumor cells (Hagemann et al., 2008).
Other studies also showed the involvement of IL-1β in myeloid
cell differentiation. Thus, IL-1β inhibits the skewing of myeloid
cells present in proangiogenic cultures from circulating angio-
genic cells to mature dendritic cells (DCs) (Mohty et al., 2003;
Denny et al., 2007). In addition, IL-1β can impair maturation in
DCs treated with rapamycin (Turnquist et al., 2008).
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Our experimental system of tumor cells encapsulated in
Matrigel plugs allows the study of the early angiogenic response
and even the angiogenic switch. In this case, VEGF produced by
ECs possibly synergizes with direct angiogenic factors secreted by
the malignant cells. Traditionally, it was thought that ECs respond
to VEGF during the angiogenic response and produce very lit-
tle or undetectable amounts of VEGF (Kerbel, 2008). In other
studies, using large, established tumors that are densely infiltrated
by “activated” myeloid cells, it was shown that VEGF mainly
originates from such myeloid cells and it controls tumor angio-
genesis (reviewed in Apte and Voronov, 2008; Murdoch et al.,
2008; Coffelt et al., 2010; Ferrara, 2010a; Mantovani and Sica,
2010; Qian and Pollard, 2010; Ruffell et al., 2010; Allavena and
Mantovani, 2012; Gabrilovich et al., 2012). In the early stages of
tumor development, as assessed in our studies, myeloid cells are
probably not yet sufficiently activated to produce VEGF. Thus, at
different stages of tumor progression, VEGF is secreted by diverse
microenvironmental cells and it acts together with angiogenic
factors of tumor cell origin.
Results of our studies have shown that IL-1β is a major medi-
ator in the tumor microenvironment, which plays a crucial role
in the angiogenic response. IL-1β acts together with VEGF in
mounting and maintaining tumor-mediated angiogenesis.
THE DIFFERENTIAL EFFECTS OF IL-1 MOLECULES IN
TUMOR-INDUCED ANGIOGENESIS AND INVASIVENESS
High levels of IL-1 molecules are found in experimental tumor
models and in human malignancies and IL-1 has been implicated
as a key factor in tumor progression. IL-1 exerts its prolifer-
ative and angiogenic effects in the tumor microenvironment,
mainly via interaction with stromal, inflammatory, as well as the
malignant cells, stimulating tumor cell proliferation and inva-
sion through autocrine or paracrine loops. For example, IL-1β
induces secretion of chemokines by both tumor and tumor-
microenvironmental cells and thus promotes cancer invasiveness
(Portier et al., 1993; Suswam et al., 2005; Apte et al., 2006a;
Naldini et al., 2010). A few studies have documented constitutive
IL-1β protein production in human and animal cancer cell lines,
including sarcomas and ovarian cell carcinomas (Dinarello, 1996;
Lewis et al., 2006). In patients, overexpression of IL-1β has been
described in solid tumors, including breast, colon, lung, head
and neck cancers, and melanomas. In some tumors, IL-1, as well
as other pro-inflammatory cytokines, is induced by oncogenes
that transform the cell, thus providing the microenvironment for
invasiveness of the malignant cells. In other types of tumors, IL-
1 is induced only in the invasiveness and metastasis phases. The
switch-on of IL-1 genes in malignant cells is induced by genetic
alterations and possibly also by microenvironment-derived sig-
nals. Indeed, high IL-1 concentrations within the tumormicroen-
vironment have been reported in numerous studies in cancer
patients and experimental models and are associated with a more
virulent tumor phenotype (reviewed in Elaraj et al., 2006; Lewis
et al., 2006).
In the tumor milieu, IL-1 induces expression of various
metastatic mediators, such as matrix metalloproteinases (MMP),
VEGF, IL-8, IL-6, TNFα, and TGFβ (reviewed in Dinarello, 1996;
Apte and Voronov, 2002, 2008; Apte et al., 2006b; Lewis et al.,
2006; Voronov et al., 2013). Previously, in a transgenic model
of Myc-dependent carcinogenesis, IL-1β was characterized as
the principal effector molecule in the onset of angiogenesis, via
MMP-mediated sequestration of extracellular matrix-associated
VEGF and its further ligation to its cognate receptor on ECs
(Shchors et al., 2006).
Our studies throughout the years have assessed the role of the
IL-1 molecules in different phases of the malignant process, such
as carcinogenesis, tumor angiogenesis, and invasiveness (Song
et al., 2003, 2005; Krelin et al., 2007). Using a transplantable
fibrosarcoma cell line transfected with cDNAs of the active forms
of IL-1β, i.e., the mature form of IL-1β or the mature form of
IL-1β ligated to a signal sequence (ssIL-1β), in which IL-1β is
actively secreted through the endoplasmic reticulum-Golgi path-
way, we observed that invasiveness of the different tumor cell lines
was directly proportional to the amount of IL-1β secreted by the
malignant cells (Song et al., 2003, 2005). In this system, invasive-
ness correlated with increased angiogenesis and accumulation of
MDSCs in the spleen and tumor, which leads to general anergy.
Similar observations were described in other experimental sys-
tems using IL-1β-transfected tumor cells (Saijo et al., 2002; Nakao
et al., 2005; Bunt et al., 2006). We have hypothesized that ini-
tially small amounts of tumor cell-derived IL-1β induce a local
inflammatory response, which subsequently recruits and activates
BMDs that further secrete IL-1β, as well as an entire cytokine
network that promotes tumor-mediated angiogenesis and tumor
progression.
In various tumor models, we found that IL-1β induces
increased tumor growth, invasiveness, and angiogenesis, when
compared to IL-1α (Song et al., 2003; Voronov et al., 2003,
2010b). However, in some tumor cells, active secretion of IL-1α
is observed (Apte and Voronov, 2008; Voronov et al., 2013).
In some tumors, such as breast carcinoma or pancreatic can-
cer, a pro-angiogenic signature correlated with IL-1α signaling
(Matsuo et al., 2009; Guo and Gonzalez-Perez, 2011; Zhou et al.,
2011). In these studies, IL-1α was shown to be involved in the
induction of VEGF/VEGFR2 in the tumor microenvironment,
through a cascade involving leptin/Notch. Secreted IL-1α may
promote invasiveness in a similar manner to secreted IL-1β in
these tumors.
However, in most malignancies, IL-1 is produced not only by
tumor cells, but by other cells, such as neutrophils, macrophages,
andMDSCs, recruited to the tumormicroenvironment (reviewed
in Apte and Voronov, 2008; Witz, 2008; Balkwill and Mantovani,
2010; Demaria et al., 2010; Grivennikov et al., 2010; Hanahan and
Weinberg, 2011; Voronov et al., 2013).
These recruited cells thereby promote inflammation in the
tumor microenvironment and thus increase the angiogenic
response, tumor cell invasiveness and metastasis (Goldberg and
Schwertfeger, 2010; Naldini et al., 2010; Schmid et al., 2011;
Carmi et al., 2013).
Using IL-1 KO mice, we demonstrated that
microenvironment-derived IL-1β, and to a much lesser
extent IL-1α, is responsible for in vivo tumor angiogenesis
and invasiveness of B16 melanoma cells. Significantly decreased
angiogenesis was observed in IL-1β deficient mice injected with
either melanoma cells or melanoma cell-containing Matrigel
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plugs, when compared to wild-type mice. In IL-1α KO mice,
tumor growth and angiogenesis in Matrigel plugs were observed
to a lesser extent than in WT mice, but higher than those in
IL-1β KO mice (Voronov et al., 2003). Addition of recombinant
IL-1 into Matrigel plugs containing B16 cells in IL-1β KO mice
partially restored the angiogenic response, while addition of
IL-1Ra to B16-containing Matrigel plugs in wild-type mice
inhibited the ingrowth of the blood vessel network into the
plugs. In subsequent studies, the angiogenic potential of IL-1 was
confirmed by Elaraj et al., who observed high expression of IL-1
mRNA in more than half of all tested metastatic human tumor
specimens, including non-small-cell lung carcinoma, colorectal
adenocarcinoma, and melanoma tumor samples. Supernatants
from IL-1 expressing cell lines induced a significant increase in
EC monolayer permeability, a hallmark event in early angiogen-
esis. Systemic treatment with recombinant IL-1Ra resulted in
significant inhibition of xenograft growth and neovessel density
of IL-1-producing tumor cell lines. Nevertheless, the addition
of IL-1Ra did not have any effect in non-IL-1-producing tumor
lines (Elaraj et al., 2006).
ANTI-IL-1 THERAPY IN ANTI-TUMOR APPROACHES
Since tumor development is related to and dependent on the
angiogenic response, anti-angiogenic therapy targeting blood ves-
sel formation was used to suppress existing tumors and to pre-
vent metastasis. Various studies used different anti-angiogenic
molecules or agents to limit tumor angiogenesis. The main
molecule used in these experiments was VEGF, which is the
most abundant pro-angiogenic molecule. A number of preclinical
studies demonstrated a significant inhibition of tumor growth in
various types of cancer by blocking VEGF (Ferrara and Kerbel,
2005). VEGF has been approved by the FDA to be used in
cancer patients to inhibit tumor growth. Anti-VEGF monoclonal
antibodies (bevacizumab, also called Avastin) were tested in var-
ious metastatic cancers in humans, usually in combination with
chemotherapy (Ferrara et al., 2005; Carmeliet and Jain, 2011).
However, some patients are refractory to this treatment and
tumor recurrence or even metastases were observed after initial
tumor shrinkage. It is beyond the scope of this review to sum-
marize the effects of anti-VEGF therapy in cancer patients. In
animal models, it was also shown that termination or interrup-
tion of VEGF neutralization induces rapid vascular regrowth in
tumors and limits tumor-suppressive effects of VEGF treatment
(reviewed in Kubota, 2012; Bellou et al., 2013). The dramatic
response of the tumor microenvironment to VEGF inhibition
may be due to the key role VEGF plays in normal cell viabil-
ity, including ECs, myeloid cells, and possibly other cell types
involved in tissue homeostasis (Chung and Ferrara, 2011; Lazarus
and Keshet, 2011; Luo et al., 2011; Potente et al., 2011). For exam-
ple, blocking VEGF induces EC apoptosis, resulting in the loss
of integrity of blood vessels, and disturbance of tissue homeosta-
sis. Due to these effects, VEGF blockage damages not only tumor
blood vessels, but also healthy vessels, thus occasionally result-
ing in severe complications, such as hemorrhagic or thrombotic
events (Verheul and Pinedo, 2007).
Different mechanisms have been proposed to explain rebound
angiogenesis following VEGF neutralization (Casanovas et al.,
2005; Ferrara, 2010b; Chung and Ferrara, 2011; Carmi et al.,
2013). For example, intrinsic mechanisms, such as the adap-
tation of malignant cells to low VEGF levels by selecting
tumor cell variants that are less dependent on VEGF for
their survival/proliferation or variants with enhanced expres-
sion/secretion of other pro-angiogenic factors, such as bFGF or
PlGF have been described (Casanovas et al., 2005; Fischer et al.,
2007; Kubota, 2012). Following VEGF neutralization, extrin-
sic mechanisms also contribute to tumor recurrence by altering
microenvironment cells to express different or additional angio-
genic factors, thus facilitating tumor recurrence. These include
induced secretion of Bv8 by MDSCs and a subsequent VEGF-
independent angiogenic response (Shojaei et al., 2007; Carmi
et al., 2013) or expression of PDGF-C in cancer-associated fibrob-
lasts (Bergers and Hanahan, 2008; Crawford et al., 2009). In our
studies, we described a novel mechanism of rebound angiogene-
sis after VEGF inhibition inMatrigel plugs containing tumor cells
(Carmi et al., 2013). This resulted in significant and consistently
elevated expression of direct angiogenic factors, such as bFGF,
PlGF, and PDGF, as well as VEGF in VEGFR1+ immaturemyeloid
cells, mostly MDSCs. The re-programming of VEGFR1+ imma-
ture myeloid cells into active pro-angiogenic cells also involves
increased expression of hypoxia-inducible factor 1α, a key tran-
scription factor regulating angiogenesis (Cramer and Johnson,
2003; Semenza, 2011). In contrast, in “uninterrupted angio-
genesis” (without anti-VEGF treatment), as described above,
ECs, rather than myeloid cells, are the major cells that pro-
duce VEGF and other direct angiogenic factors (Carmi et al.,
2013).
In recent years, myeloid, cell-driven angiogenesis was shown to
contribute to refractoriness or resistance to VEGF inhibition. For
example, as discussed above, MDSCs can secrete Bv8, which fur-
ther upregulates granulocyte colony-stimulating factor that pro-
motes tumor growth and angiogenesis in a VEGF-independent
manner. Therefore, intervention in myeloid cell recruitment to
tumor sites in order to modulate differentiation or neutralization
of specific pro-inflammatory or pro-angiogenic factors secreted
by these cells, are now widely discussed. For example, blocking
CSF-1 was shown to be effective in suppressing tumor angio-
genesis (Kubota, 2012). In our studies, we found that blocking a
major, alarm, pro-inflammatory molecule derived from myeloid
cells, i.e., IL-1β can lead to a significant amelioration of tumor
angiogenesis (Voronov et al., 2003; Carmi et al., 2013). The
inhibition of IL-1β does not affect the healthy vascular system
or tissue homeostasis and is more suitable for anti-angiogenic
therapy than anti-VEGF approaches. IL-1β neutralization largely
inhibited infiltration of myeloid cells, which are obligatory for
tumor-mediated angiogenesis. Furthermore, IL-1β neutralization
induces maturation of immature myeloid cells into anti-invasive
M1 macrophages.
We recently found that IL-1β neutralization inhibited pro-
inflammatory genes, such as Bv8, CCL2 and CCL3 in myeloid
cells, and did not significantly alter the expression of angiogenic
factors. IL-1β inhibition also reduced in vivo tumor development
in mice injected subcutaneously with tumor cells. This inhibi-
tion was long-lasting and without recurrence a contrast to that
observed with anti-VEGF (Carmi et al., 2013).
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FIGURE 1 | Crosstalk between IL-1β and VEGF in the tumor
microenvironment. (A) In the tumor microenvironment, IL-1β can be
expressed initially by the malignant cells. In turn, IL-1β can recruit myeloid
cells from the BM and further activate them to secrete pro-inflammatory and
pro-angiogenic molecules, such as VEGF and IL-1β. Furthermore, IL-1β keeps
myeloid cells in their immature stage, where they are pro-invasive and
immunosuppressive. IL-1β can also activate tissue-resident ECs to produce
VEGF and other pro-angiogenic factors. The malignant cells can also be
activated by IL-1β for increased invasiveness. VEGF in the tumor
microenvironment activates ECs and myeloid cells and also has homeostatic
effects on these cells. (B) In the absence of IL-1β, inflammation, as well as
VEGF production is diminished, which results in reduced invasiveness. Lack
of IL-1β in the tumor microenvironment also induces the maturation of
MDSCs into anti-tumor M1 macrophages.
These results have provided the rationale to use IL-1β neu-
tralization as a treatment for tumor-mediated angiogenesis, and
subsequent tumor progression.
Indeed, the positive role IL-1Ra plays in reducing the angio-
genic response and in attenuating tumor progression has been
demonstrated by us (Song et al., 2003; Voronov et al., 2003)
and by others (Saijo et al., 2002; Nakao et al., 2005; Bunt
et al., 2006; Schmid et al., 2011). IL-1 neutralization agents are
available at the present time (Dinarello, 2010a,b; Dinarello and
van der Meer, 2012). The IL-1Ra, also called Anakirna (Kineret;
Amgen/Biovitrum) has been shown to be safe and effective in
alleviating symptoms of rheumatoid arthritis and other auto-
inflammatory diseases. Continuous delivery systems of recombi-
nant IL-1Ra or cells over-expressing IL-1Ra, encapsulated within
alginate-poly (L-lysine)-alginate (APA) microspheres, reduced
the tumor burden and inhibited tumor-mediated angiogene-
sis when implanted into tumor-bearing mice (Bar et al., 2004;
Lavi et al., 2007). Similarly, over-expression of the IL-1Ra in
human melanoma cell lines expressing endogenous IL-1, inhibits
tumor growth and metastasis in human melanoma xenografts
in nude mice through its effects on the microenvironment
(Weinreich et al., 2003; Elaraj et al., 2006). Altogether, these
results provide pre-clinical support for the use of IL-1Ra in cancer
therapy.
Recently, some novel IL-1 neutralization agents, such as
humanized anti-IL-1β, an IL-1 trap, as well as other agents
that indirectly inhibit IL-1β production, have been devel-
oped (Dinarello, 2011b). These agents are now ready for test-
ing in cancer patients. Optimally, IL-1 neutralization should
be most effective in patients with minimal residual disease
(MRD), to prevent tumor-induced angiogenesis, recurrence, and
metastasis.
CONCLUSIONS
Finally, this review demonstrated the important role of the IL-1
family molecules, especially IL-1β, in the tumor microenviron-
ment. IL-1β represents a major upstream cytokine that controls
the local pro-inflammatory cascade and thereby affects the bal-
ance between protective immunity and destructive inflammation.
IL-1 modulates diverse cells in the tumor microenvironment and
acts together with VEGF in mounting and maintaining tumor-
mediated angiogenesis (Figure 1). Thus, its neutralization should
reduce tumor progression and invasiveness via its affect on pro-
tumorigenic cells, and on the tumor-induced angiogenic switch.
Further characterization of the optimal conditions for IL-1 neu-
tralization could lead to the application of anti-IL-1 approaches
in cancer therapy.
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